# A Prospective Clinical Study of CD3-CD20 Bisspecific Antibody Based Therapy Combined With CD19-CAR T Cells in the Treatment of Relapsed Refractory B-cell Non-Hodgkin Lymphoma

> clinical trial · VERIFIED · 2026-07-02

Status: ACTIVE_NOT_RECRUITING · Sponsor: Institute of Hematology & Blood Diseases Hospital, China · Condition: B-cell Non-Hodgkin Lymphoma

- Company: Institute of Hematology & Blood Diseases Hospital, China
- Sector: oncology
- Primary source: https://clinicaltrials.gov/study/NCT06464185

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED. Informational only, not investment advice. Corrections: media@medfuelinc.com.